Novel AKR1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: A phase 1 study.

Isabella GashawStefanie ReifHerbert WiesingerAndreas KaiserFrank S ZollmannChristian ScheeransJoachim GrevelPaolo PirainoHenrik SeidelMichaele PetersAntje RottmannBeate RohdeWiebeke Arlt Jan Hilpert

Published in: European journal of endocrinology (2023)

Serum androsterone was identified as a robust response biomarker for AKR1C3 inhibitor treatment in women. AKR1C3 inhibitor administration for 4 weeks did not affect ovarian function.

Keyphrases

polycystic ovary syndrome
pregnancy outcomes
type diabetes
open label
clinical trial
cervical cancer screening
breast cancer risk
insulin resistance
metabolic syndrome
skeletal muscle
combination therapy